We at Orbit Biotech understand that research is matter of high Intellectual Property and similar level of business ethics need to be followed while dealing with sensitive research. To safeguard the research of the outsourcing clients throughout the globe, a CDA (Confidential Disclosure Agreement) is signed with mutual terms and conditions related to research. The CDA ensures that the integrity of the research is maintained and respected.
Outsourcing Research has noted benefits as compared to in-house research Accelerated Research Research by experts and experienced professionals Cost Reduction Accurate research results Latest Survey on CRO A significant portion of R&D budgets are used for the outsourcing services offered by the CRO industry, approximately $15 billion in 2007. This figure is expected to grow at 15% over the next seven years and should increase further with the broadening of the spectrum of services outsourced to cover the entire value chain.
As outsourced services in developing countries such as China and India move up the value chain to cover phase 1/2 trials, the total contracts value may go up to $20 billion by 2010. Further, certain therapeutic areas within pharmaceutical development are slated for an even greater growth curve, namely the oncology class, expected to see continued growth of upwards of 21% over the next few years due to the large target market, strong unmet medical need, and overwhelming number of drugs currently in development (667 for cancer vs. 252 for CNS disorders, 206 for cadiovascular disorders, and 186 for infections). There are over 1,100 companies in the world.It is a very fragmented industry with the top 10 controlling 56.1% of the market.
* Courtsey: “New Research offers CRO market snapshot” , Kirsty Barnes, Outsourcing-Pharma ” Celticor Clinical Research and Site Management Coimbatore